---
title: Assessing Sedentary Behaviour in Adults With Type 2 Diabetes - A Randomized Controlled Trial
nct_id: NCT05505864
overall_status: UNKNOWN
phase: NA
sponsor: Western University
study_type: INTERVENTIONAL
primary_condition: Sedentary Behavior
countries: Canada
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05505864.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05505864"
ct_last_update_post_date: 2023-01-18
last_seen_at: "2026-05-12T06:35:51.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Assessing Sedentary Behaviour in Adults With Type 2 Diabetes - A Randomized Controlled Trial

**Official Title:** A Combined Health Action Process Approach and mHealth Intervention to Assess Sedentary Behaviour in Adults With Type 2 Diabetes - A Randomized Controlled Trial

**NCT ID:** [NCT05505864](https://clinicaltrials.gov/study/NCT05505864)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 52
- **Lead Sponsor:** Western University
- **Conditions:** Sedentary Behavior, Diabetes Mellitus, Type 2, Adult ALL
- **Start Date:** 2022-10-01
- **Completion Date:** 2023-09
- **CT.gov Last Update:** 2023-01-18

## Brief Summary

The purpose of this health behaviour change research study is to assist adults with T2D in achieving the Canadian 24-hour sedentary behaviour movement guidelines.

## Detailed Description

Adults with type 2 diabetes (T2D) are less active and accumulate more sedentary behaviour (SB) than those without. Among adults with T2D, increased SB is associated with increased mortality after adjusting for physical activity. Canadian 24-hour SB movement guidelines recommend limiting SB to ≤8 hours, no more than 3 hours of recreational screen time, and breaking up long periods of SB as often as possible. Therefore, the purpose of this research study is for adults with T2D to achieve these SB Canadian 24-hour SB movement guidelines. To address this purpose, we will be conducting a six-week two-arm repeated measures randomized control trial. The intervention group will receive a theory-based behaviour change counselling session through zoom at week 0, mobile phone application at weeks 2 and 4 that encourage participants to create their own personal and specific action plans and coping strategies, and daily text messages that motivate participants to reduce and break up their SB. The control group will receive no intervention. The primary objective of the study is to reduce SB, while the secondary objectives are to break up SB, reduce screen time, improve quality of life, determine the perceptions towards the intervention, and validate the SB questionnaires. SB will be collected in the form of total daily SB, frequency of SB breaks, and duration of SB breaks. These variables will be measured through a SB and quality of life questionnaires that will be delivered through a downloadable mobile phone application. Outcome measures will be compared within and between groups to detect differences.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 18 years or older
* diagnosed with type 2 diabetes
* access to a smart phone with internet connection
* be able to read, write, and speak in english

Exclusion Criteria:

* any medical or physical limitation that would prevent standing, stretching, and/or light physical activity
```

## Arms

- **Intervention Group** (EXPERIMENTAL) — * Participants in the intervention group will be asked to wear an ACTIVPAL4 at week 0, 5, and 11.
* Participants in the intervention group will be asked to fill out questionnaires assessing key variable (demographics, sedentary behaviour, and quality of life) on the SEMA3 app at week 0, 2, 4, 6, and 12.
* Participants in the intervention group will receive a one-on-one behavioural counselling session online through zoom at week 0 to create personalized action plans and coping strategies to reduce and break up sedentary behaviour. The participant will update these action plans and coping strategies at the end of week 2 and 4 on the SEMA3 app.
* Participants in the intervention group will receive tailored text messages the day after receiving their one-on-one counselling session for a 6-week period.
* Participants in the intervention will receive one-on-one qualitative interview on zoom at week 6 to explore participants overall experience engaging in the intervention.
- **Control Group** (NO_INTERVENTION) — * Participants in the control group will be asked to wear an ACTIVPAL4 at week 0, 5, and 11.
* Participants in the control group will be asked to fill out questionnaires assessing key variable (demographics, sedentary behaviour, and quality of life) on the SEMA3 mobile app at week 0, 2, 4, 6, and 12.

## Interventions

- **Health Action Process Approach (HAPA)** (BEHAVIORAL) — Health Action Process Approach (HAPA) using action planning and coping strategies to create health behaviour change

## Primary Outcomes

- **Self-reported total sedentary behaviour** _(time frame: Measured at week 0.)_ — Measured by the modified sedentary behaviour questionnaire (SBQ). Where total daily sedentary behaviour ranges from 0 to 24 hours. Higher number of hours is worse.
- **Self-reported total sedentary behaviour** _(time frame: Measured at week 2.)_ — Measured by the modified sedentary behaviour questionnaire (SBQ). Where total daily sedentary behaviour ranges from 0 to 24 hours. Higher number of hours is worse.
- **Self-reported total sedentary behaviour** _(time frame: Measured at week 4.)_ — Measured by the modified sedentary behaviour questionnaire (SBQ). Where total daily sedentary behaviour ranges from 0 to 24 hours. Higher number of hours is worse.
- **Self-reported total sedentary behaviour** _(time frame: Measured at week 6.)_ — Measured by the modified sedentary behaviour questionnaire (SBQ). Where total daily sedentary behaviour ranges from 0 to 24 hours. Higher number of hours is worse.
- **Self-reported total sedentary behaviour** _(time frame: Measured at week 12.)_ — Measured by the modified sedentary behaviour questionnaire (SBQ). Where total daily sedentary behaviour ranges from 0 to 24 hours. Higher number of hours is worse.
- **Objectively measured total sedentary behaviour** _(time frame: Measured at week 0.)_ — Measured by the ACTIVPAL4
- **Objectively measured total sedentary behaviour** _(time frame: Measured at week 6.)_ — Measured by the ACTIVPAL4
- **Objectively measured total sedentary behaviour** _(time frame: Measured at week 12.)_ — Measured by the ACTIVPAL4

## Secondary Outcomes

- **Self-reported sedentary behaviour break frequency** _(time frame: Measured at week 0.)_
- **Self-reported sedentary behaviour break frequency** _(time frame: Measured at week 2.)_
- **Self-reported sedentary behaviour break frequency** _(time frame: Measured at week 4.)_
- **Self-reported sedentary behaviour break frequency** _(time frame: Measured at week 6.)_
- **Self-reported sedentary behaviour break frequency** _(time frame: Measured at week 12.)_
- **Self-reported sedentary behaviour break duration** _(time frame: Measured at week 0.)_
- **Self-reported sedentary behaviour break duration** _(time frame: Measured at week 2.)_
- **Self-reported sedentary behaviour break duration** _(time frame: Measured at week 4.)_
- **Self-reported sedentary behaviour break duration** _(time frame: Measured at week 6.)_
- **Self-reported sedentary behaviour break duration** _(time frame: Measured at week 12.)_
- **Self-reported screen time** _(time frame: Measured at week 0.)_
- **Self-reported screen time** _(time frame: Measured at week 2.)_
- **Self-reported screen time** _(time frame: Measured at week 4.)_
- **Self-reported screen time** _(time frame: Measured at week 6.)_
- **Self-reported screen time** _(time frame: Measured at week 12.)_
- **Objective sedentary behaviour break frequency** _(time frame: Measured at week 0.)_
- **Objective sedentary behaviour break frequency** _(time frame: Measured at week 6.)_
- **Objective sedentary behaviour break frequency** _(time frame: Measured at week 12.)_
- **Objective sedentary behaviour break duration** _(time frame: Measured at week 0.)_
- **Objective sedentary behaviour break duration** _(time frame: Measured at week 6.)_
- **Objective sedentary behaviour break duration** _(time frame: Measured at week 12.)_
- **Self-reported quality of life** _(time frame: Measured at week 0.)_
- **Self-reported quality of life** _(time frame: Measured at week 6.)_
- **Self-reported quality of life** _(time frame: Measured at week 12.)_
- **Overall experience of the intervention** _(time frame: Measured at week 6.)_
- **Validate the modified sedentary behaviour questionnaire (SBQ)** _(time frame: Measured at week 0.)_
- **Validate the modified SIT-Q (no unabbreviated name) questionnaire** _(time frame: Measured at week 0.)_
- **Validate the modified sedentary behaviour questionnaire (SBQ)** _(time frame: Measured at week 6.)_
- **Validate the modified SIT-Q (no unabbreviated name) questionnaire** _(time frame: Measured at week 6.)_
- **Validate the modified sedentary behaviour questionnaire (SBQ)** _(time frame: Measured at week 12.)_
- **Validate the modified SIT-Q (no unabbreviated name) questionnaire** _(time frame: Measured at week 12.)_

## Locations (1)

- Harry Prapavessis, London, Ontario, Canada — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.harry prapavessis|london|ontario|canada` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05505864.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05505864*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*